Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epigenomics Signs Licensing and Supply Agreement with Kindstar

Published: Friday, January 10, 2014
Last Updated: Thursday, January 09, 2014
Bookmark and Share
Agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.

Epigenomics AG and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar) have announced that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.

Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.

Noel Doheny, CEO of Epigenomics' US subsidiary, commented: "We are excited to enter into this agreement regarding our Epi proLung® tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung® in China. This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market.”

“Epigenomics’ Epi proLung® assay fills an unmet need in current lung cancer diagnosis,” added Shiang Huang, M.D., CEO of Kindstar.

Huang continued, “We are very pleased to add Epi proLung® to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epigenomics AG Announces 2014 Third Quarter Financial Results
Epigenomics AG has announced its financial results for the third quarter and the nine months 2014 ending September 30.
Tuesday, November 11, 2014
Polymedco Continues to Support Epi proColon(R)
Epigenomics' strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States.
Monday, November 03, 2014
Epigenomics AG Announces Non-exclusive Licensing Agreement with Companion Dx
Companion Dx has obtained rights to establish and commercialize a laboratory-developed test to detect colorectal cancer.
Friday, June 22, 2012
Epigenomics Successfully Optimized Assay Procedure for Cancer Screening Tests
Epigenomics AG has reached a milestone in completing the work on an optimized assay procedure for its blood-based cancer screening tests.
Tuesday, July 03, 2007
Epigenomics Demonstrates Feasibility of Convenient Blood Test for Lung
Epigenomics has announced positive data resulting from a clinical study as part of its lung cancer screening test development program.
Thursday, June 28, 2007
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!